CoChat

Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis

Open access
Siafis, Spyridon, Wu, Hui, Wang, Dongfang, Burschinski, Angelika, Nomura, Nobuyuki, Takeuchi, Hiroyoshi, Schneider-Thoma, Johannes, Davis, John M., Leucht, Stefan · 2023 · Molecular Psychiatry
Cited by 161

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Antipsychotic drugs differ in their propensity to cause extrapyramidal side-effects (EPS), but their dose-effects are unclear. Therefore, we conducted a systematic review and dose-response meta-analysis. We searched multiple electronic databases up to 20.02.2023 for fixed-dose studies investigating 16 second-generation antipsychotics and haloperidol (all formulations and administration routes) in adults with acute exacerbations of schizophrenia. The primary outcome was the number of participants receiving antiparkinsonian medication, and if not available, the number of participants with extrapyramidal side-effects (EPS) and the mean scores of EPS rating scales were used as proxies. The effect-size was odds ratio (ORs) compared with placebo. One-stage random-effects dose-response meta-analyses with restricted cubic splines were conducted to estimate the dose-response curves. We also examined the relationship between dopamine D 2 receptor (D 2 R) occupancy and ORs by estimating occupancies from administrated doses. We included data from 110 studies with 382 dose arms (37193 participants). Most studies were short-term with median duration of 6 weeks (range 3–26 weeks). Almost all antipsychotics were associated with dose-dependent EPS with varied degrees and the maximum ORs ranged from OR = 1.57 95%CI [0.97, 2.56] for aripiprazole to OR = 7.56 95%CI [3.16, 18.08] for haloperidol at 30 mg/d. Exceptions were quetiapine and sertindole with negligible risks across all doses. There was very low quality of findings for cariprazine, iloperidone, and zotepine, and no data for clozapine. The D 2 R occupancy curves showed that the risk increased substantially when D 2 R occupancy exceeded 75–85%, except for D 2 R partial agonists that had smaller ORs albeit high D 2 R occupancies. In conclusion, we found that the risk of EPS increases with rising doses and differs substantially in magnitude among antipsychotics, yet exceptions were quetiapine and sertindole with negligible risks. Our data provided additional insights into the current D 2 R therapeutic window for EPS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-023-02203-y

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 57

  1. Stahl SM, Sy S, Maguire GA. How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. Acta Psychiatr Scand. 2021;143:172–80. · DOI
  2. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30:531–40. · DOI
  3. Joshi YB, Thomas ML, Braff DL, Green MF, Gur RC, Gur RE, et al. Anticholinergic medication burden–associated cognitive impairment in schizophrenia. Am J Psychiatry. 2021;178:838–47. · DOI · Paper page
  4. Ginovart N, Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharm. 2012;212:27–52. · DOI · Paper page
  5. Siafis S, Davis JM, Leucht S. Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-Nomenclature. Psychol Med. 2021;51:522–4. · DOI
  6. Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704. · DOI · Paper page
  7. Kenakin T. Principles: receptor theory in pharmacology. Trends Pharm Sci. 2004;25:186–92. · DOI · Paper page
  8. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51:9–62. · DOI · Paper page
  9. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:497–502. · DOI
  10. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538–44. · DOI · Paper page
  11. Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J, et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis. JAMA Psychiatry. 2021;78:1238–48. · DOI
  12. de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. Aaps j. 2011;13:121–30. · DOI
  13. Nguyen TT, Pariente A, Montastruc JL, Lapeyre-Mestre M, Rousseau V, Rascol O, et al. An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders. Br J Clin Pharm. 2017;83:612–22. · DOI
  14. Olten B, Bloch MH. Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;84:272–81. · DOI
  15. Sykes DA, Lochray J, Comfort HM, Jain P, Charlton SJ. Exploring the kinetic selectivity of antipsychotics for dopamine D2 and 5-HT2A receptors: implications for the prevalence of EPS and receptor occupancy. bioRxiv 2021:2021–11. · DOI
  16. Yoshida K, Takeuchi H. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behav Brain Res. 2021;402:113098. · DOI
  17. Schneider-Thoma J, Efthimiou O, Bighelli I, Dörries C, Huhn M, Krause M, et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6:753–65. · DOI
  18. Wu H, Siafis S, Hamza T, Schneider-Thoma J, Davis JM, Salanti G, et al. Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. Schizophr Bull. 2022;48:643–54. · DOI
  19. Younis IR, Gopalakrishnan M, Mathis M, Mehta M, Uppoor R, Zhu H, et al. Association of end point definition and randomized clinical trial duration in clinical trials of schizophrenia medications. JAMA Psychiatry. 2020;77:1064–71. · DOI
  20. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Wiley and Sons: Chichester, UK, 2011.
  21. Whiting-O'Keefe QE, Henke C, Simborg DW. Choosing the correct unit of analysis in Medical Care experiments. Med Care. 1984;22:1101–14. · DOI · Paper page
  22. Shokraneh F, Adams CE. Cochrane Schizophrenia group’s study-based register of randomized controlled trials: development and content analysis. Schizophrenia Bull Open. 2020;1:sgaa061. · DOI
  23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19. · DOI · Paper page
  24. Bakbergenuly I, Hoaglin DC, Kulinskaya E. Pitfalls of using the risk ratio in meta-analysis. Res Synth Methods. 2019;10:398–419. · DOI · Paper page
  25. Doi SA, Furuya-Kanamori L, Xu C, Chivese T, Lin L, Musa OAH, et al. The Odds Ratio is "portable" across baseline risk but not the Relative Risk: Time to do away with the log link in binomial regression. J Clin Epidemiol. 2022;142:288–93. · DOI
  26. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000;19:3127–31. · DOI · Paper page
  27. Crippa A, Orisini N. Multivariate dose-response meta-analysis: the dosresmeta R package. J Stat Softw, Code Snippets. 2016;72:1–15.
  28. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60:974–7. · DOI · Paper page
  29. de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J. 2011;13:121–30. · DOI
  30. Puech A, Fleurot O. Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. Acta PsychiatrScand. 1998;98:65–72. · DOI
  31. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch psychiatry Clin Neurosci. 2018;268:625–39. · DOI · Paper page
  32. Meltzer HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone improves psychopathology and cognition in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2020;40:240. · DOI
  33. Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28:392–400. · DOI
  34. Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scandinavica. 2006;114:319–27. · DOI
  35. Honer WG, MacEwan GW, Gendron A, Stip E, Labelle A, Williams R, et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73:13–20. · DOI
  36. Lindenmayer JP, Citrome L, Khan A, Kaushik S, Kaushik S. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2011;31:160–8. · DOI
  37. Sabe M, Zhao N, Crippa A, Kaiser S. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. npj Schizophrenia. 2021;7:1–11. · DOI
  38. Kasper S, Tauscher J, Küfferle B, Barnas C, Hesselmann B, Asenbaum S, et al. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study. Psychopharmacol (Berl). 1998;136:367–73. · DOI
  39. Vanover KE, Davis RE, Zhou Y, Ye W, Brašić JR, Gapasin L, et al. Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology. 2019;44:598–605. · DOI · Paper page
  40. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18 F]fallypride. Neuropsychopharmacology. 2008;33:3111–25. · DOI
  41. Hart XM, Schmitz CN, Gründer G. Molecular imaging of dopamine partial agonists in humans: implications for clinical practice. Front Psychiatry. 2022;13:832209. · DOI
  42. de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015;29:773–99. · DOI · Paper page
  43. Girgis RR, Forbes A, Abi-Dargham A, Slifstein M. A positron emission tomography occupancy study of brexpiprazole at dopamine D(2) and D(3) and serotonin 5-HT(1 A) and 5-HT(2 A) receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology. 2020;45:786–92. · DOI
  44. Girgis RR, Slifstein M, D’Souza D, Lee Y, Periclou A, Ghahramani P, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-( + )-PHNO. Psychopharmacol (Berl). 2016;233:3503–12. · DOI
  45. Mohr P, Masopust J, Kopeček M. Dopamine receptor partial agonists: Do they differ in their clinical efficacy? Front Psychiatry. 2021;12:781946. · DOI
  46. Wu H, Siafis S, Wang D, Burschinski A, Schneider-Thoma J, Priller J, et al. Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis. Eur Neuropsychopharmacol. 2023;72:40–9. · DOI
  47. Siafis S, Bursch N, Müller K, Schmid L, Schuster F, Waibel J, et al. Evidence-based shared-decision-making assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia. BMC Psychiatry. 2022;22:406. · DOI
  48. Rodolico A, Siafis S, Bighelli I, Samara MT, Hansen WP, Salomone S, et al. Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. Cochrane Database Syst Rev. 2022;11:Cd014384.
  49. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38:167–77. · DOI · Paper page
  50. Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D. Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. Neuropsychiatr Dis Treat. 2013;9:1381–92. · DOI
  51. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28:203–9. · DOI · Paper page
  52. Yu C-L, Carvalho AF, Thompson T, Tsai T-C, Tseng P-T, Hsu C-W, et al. Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia. BMJ Ment Health. 2023;26:e300546. · DOI
  53. Leucht S, Huhn M, Davis JM. Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia? Eur Arch Psychiatry Clin Neurosci. 2021;271:1411–3. · DOI
  54. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192–208. · DOI · Paper page
  55. Brunoni AR, Tadini L, Fregni F. Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. PLoS One. 2010;5:e9479. · DOI
  56. Pope A, Adams C, Paton C, Weaver T, Barnes TR. Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. Br J Psychiatry. 2010;197:67–72. · DOI
  57. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. Bmj. 1998;317:1181–4. · DOI · Paper page

Metadata

Authors
Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider-Thoma, J., Davis, J. M., & Leucht, S.
Venue
Molecular Psychiatry
Published
2023-08
Volume
28
Issue
8
Pages
3267-3277
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4385552687
Cited by
161
References
18
FWCI
9.62
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. https://app.cochat.ai/papers/10.1038/s41380-023-02203-y
The paper
Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider-Thoma, J., Davis, J. M., & Leucht, S. (2023). Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Molecular Psychiatry. https://doi.org/10.1038/s41380-023-02203-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.